       Document 0751
 DOCN  M9610751
 TI    Evaluation of murine leukemia virus infection as a model for
       thrombocytopenia of HIV/AIDS: mechanism of thrombocytopenia and
       modulation of thrombocytopenia by thrombopoietin.
 DT    9601
 AU    Sullivan PS; McDonald TP; Department of Animal Science, College of
       Veterinary Medicine,; University of Tennessee, Knoxville 37901, USA.
 SO    AIDS Res Hum Retroviruses. 1995 Jul;11(7):837-42. Unique Identifier :
       AIDSLINE MED/96053847
 AB    Infection of mice with the murine leukemia virus (LP-BM5) was evaluated
       as a model for the thrombocytopenia of HIV/AIDS. Percent 35S
       incorporation into platelets, platelet size, platelet count,
       platelet-associated immunoglobulins (PAIgG), and megakaryocyte size and
       number were evaluated over a period of 3-9 weeks postinfection (PI).
       Thrombopoietin from human embryonic kidney cells was administered to
       mice 9 weeks PI, and similar indices of platelet production were
       measured 2, 3, and 4 days after treatment with a biological preparation
       of thrombopoietin (thrombocytopoiesis-stimulating factor, or TSF).
       Platelet counts decreased in a time-dependent fashion (p = 0.0006)
       following infection, reaching a nadir at 8 weeks PI (82% of control
       values). Percent 35S incorporation into platelets also decreased over
       the 9-week period (p = 0.0001), falling to 63% of control values by week
       9. Additionally, platelet volume increased in a linear fashion (p =
       0.01), rising to 105% of control values by week 9. No changes in PAIgG
       were noted over the 9-week period. Megakaryocyte numbers in the femoral
       marrow were decreased at 8 weeks PI (p = 0.02, 78% of control values),
       while increased mean megakaryocyte size (p = 0.007, 116% of controls)
       was noted in the same animals. Increased numbers of naked megakaryocyte
       nuclei were observed at 3 weeks PI (p < 0.05, 208% of control values).
       Administration of 2 U/mouse of a highly purified preparation of TSF to
       virus-infected, thrombocytopenic mice resulted in increased
       thrombocytopoiesis, as compared to human serum albumin-treated,
       virus-infected controls.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Acquired Immunodeficiency Syndrome/*BLOOD  Animal  Bone
       Marrow/CYTOLOGY/PATHOLOGY  Cell Line  Disease Models, Animal
       Hematopoietic Stem Cells/CYTOLOGY/PATHOLOGY  Human  *HIV  HIV
       Infections/*BLOOD  Kidney  *Leukemia Viruses, Murine  Male
       Megakaryocytes/CYTOLOGY/PATHOLOGY  Mice  Mice, Inbred C57BL  Platelet
       Count  Regression Analysis  Retroviridae Infections/*BLOOD  Support,
       U.S. Gov't, P.H.S.  Thrombocytopenia/*ETIOLOGY/PATHOLOGY/*THERAPY
       Thrombopoietin/*THERAPEUTIC USE  Time Factors  Tumor Virus
       Infections/*BLOOD  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

